Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

[Cervical cancer screening: past--present--future].

Breitenecker G.

Pathologe. 2009 Dec;30 Suppl 2:128-35. doi: 10.1007/s00292-009-1189-1. German.

PMID:
19756616
2.

[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].

Della Palma P, Moresco L, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43. Italian.

3.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

4.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

5.

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL.

Sex Health. 2010 Sep;7(3):376-82. doi: 10.1071/SH10022. Review.

PMID:
20719230
6.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
7.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.

Lancet Oncol. 2011 Jul;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. Epub 2011 Jun 16. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

8.

[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Review. Italian.

9.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.

PMID:
24332297
10.

Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

Adams M, Jasani B, Fiander A.

Vaccine. 2007 Apr 20;25(16):3007-13. Epub 2007 Jan 18. Review.

PMID:
17292517
11.
12.

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.

El-Zein M, Richardson L, Franco EL.

J Clin Virol. 2016 Mar;76 Suppl 1:S62-S68. doi: 10.1016/j.jcv.2015.11.020. Epub 2015 Nov 18. Review.

13.

[Summary of the practice guideline 'Prevention and early diagnosis of cervical cancer' of the Dutch College of General Practitioners].

Janssen PG, Boomsma LJ, Buis PA, Collette C, Boukes FS, Goudswaard AN.

Ned Tijdschr Geneeskd. 2009;153:A517. Review. Dutch.

PMID:
20051149
14.

Cervical cancer: screening and prevention.

Behtash N, Mehrdad N.

Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):683-6. Review.

15.

What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.

Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G.

Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Epub 2009 Aug 18. Review.

PMID:
19695870
16.

[Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL)].

Krajowa Izba Diagnostów Laboratoryjnych; Polskie Towarzystwo Ginekologiczne.

Ginekol Pol. 2013 May;84(5):395-9. Polish.

PMID:
23819408
17.

Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.

PMID:
23543559
18.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
19.

Integrating human papillomavirus vaccination in cervical cancer control programmes.

Franco EL, Coutlée F, Ferenczy A.

Public Health Genomics. 2009;12(5-6):352-61. doi: 10.1159/000214925. Epub 2009 Aug 11. Review.

PMID:
19684447
20.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

PMID:
14970277

Supplemental Content

Support Center